| # | Title | Journal | Year | Citations |
|---|
| 1 | American Society of Hematology 2019 guidelines for immune thrombocytopenia | Blood Advances | 2019 | 684 |
| 2 | American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism | Blood Advances | 2020 | 636 |
| 3 | Updated international consensus report on the investigation and management of primary immune thrombocytopenia | Blood Advances | 2019 | 593 |
| 4 | American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients | Blood Advances | 2018 | 492 |
| 5 | American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia | Blood Advances | 2018 | 448 |
| 6 | American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer | Blood Advances | 2021 | 431 |
| 7 | American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy | Blood Advances | 2018 | 328 |
| 8 | American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy | Blood Advances | 2018 | 317 |
| 9 | American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 | Blood Advances | 2021 | 310 |
| 10 | American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients | Blood Advances | 2019 | 299 |
| 11 | American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism | Blood Advances | 2018 | 273 |
| 12 | American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism | Blood Advances | 2018 | 271 |
| 13 | Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma | Blood Advances | 2020 | 263 |
| 14 | Epidemiology of AL amyloidosis: a real-world study using US claims data | Blood Advances | 2018 | 260 |
| 15 | ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease | Blood Advances | 2021 | 246 |
| 16 | Targeted deep sequencing in polycythemia vera and essential thrombocythemia | Blood Advances | 2016 | 243 |
| 17 | American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support | Blood Advances | 2020 | 241 |
| 18 | A neutrophil activation signature predicts critical illness and mortality in COVID-19 | Blood Advances | 2021 | 241 |
| 19 | Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma | Blood Advances | 2020 | 238 |
| 20 | Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States | Blood Advances | 2017 | 228 |
| 21 | Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma | Blood Advances | 2020 | 222 |
| 22 | First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab | Blood Advances | 2020 | 215 |
| 23 | Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 | Blood Advances | 2017 | 207 |
| 24 | American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults | Blood Advances | 2020 | 206 |
| 25 | A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma | Blood Advances | 2020 | 198 |
| 26 | American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain | Blood Advances | 2020 | 184 |
| 27 | Targeted deep sequencing in primary myelofibrosis | Blood Advances | 2016 | 182 |
| 28 | Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity | Blood Advances | 2018 | 167 |
| 29 | Ethnicity, sex, and age are determinants of red blood cell storage and stress hemolysis: results of the REDS-III RBC-Omics study | Blood Advances | 2017 | 164 |
| 30 | First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia | Blood Advances | 2019 | 164 |
| 31 | The clinical spectrum of Erdheim-Chester disease: an observational cohort study | Blood Advances | 2017 | 163 |
| 32 | Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies | Blood Advances | 2020 | 162 |
| 33 | Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma | Blood Advances | 2017 | 155 |
| 34 | ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease | Blood Advances | 2021 | 152 |
| 35 | Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases | Blood Advances | 2017 | 151 |
| 36 | Clinical consequences of clonal hematopoiesis of indeterminate potential | Blood Advances | 2018 | 149 |
| 37 | Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib | Blood Advances | 2019 | 145 |
| 38 | CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy | Blood Advances | 2019 | 145 |
| 39 | Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma | Blood Advances | 2018 | 143 |
| 40 | Pharmacologic control of CAR-T cell function using dasatinib | Blood Advances | 2019 | 143 |
| 41 | US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL | Blood Advances | 2016 | 142 |
| 42 | IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells | Blood Advances | 2017 | 135 |
| 43 | Soluble interleukin-2 receptor is a sensitive diagnostic test in adult HLH | Blood Advances | 2017 | 134 |
| 44 | High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma | Blood Advances | 2020 | 134 |
| 45 | Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma | Blood Advances | 2020 | 134 |
| 46 | T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma | Blood Advances | 2019 | 133 |
| 47 | Evaluating measurable residual disease in acute myeloid leukemia | Blood Advances | 2018 | 132 |
| 48 | Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation | Blood Advances | 2018 | 132 |
| 49 | Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML | Blood Advances | 2020 | 129 |
| 50 | The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19 | Blood Advances | 2020 | 128 |
